Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial

Overview of attention for article published in Lancet Neurology, May 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news: 10 news outlets
blogs: 2 blogs
twitter: 36 X users

facebook: 1 Facebook page
wikipedia: 1 Wikipedia page
guideline: 1 clinical guideline source

Readers on

mendeley: 171 Mendeley

So far, Altmetric has seen 40 X posts from 36 X users, with an upper bound of 52,775 followers.

Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial https://t.co/luD13McAUb

15/25 Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial https://t.co/6QLUjewn2K

Open Access UCL Research: Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial https://t.co/X0QxqM41pn

RT @NeuroInfanti: Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a ra…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 36 additional X posts.